ピマセルチブ
ピマセルチブ 物理性質
- 沸点 :
- 623.2±55.0 °C(Predicted)
- 比重(密度) :
- 1.769
- 貯蔵温度 :
- Store at -20°C
- 溶解性:
- ≥21.55 mg/mL in DMSO; insoluble in H2O; ≥10.36 mg/mL in EtOH with ultrasonic
- 外見 :
- solid
- 酸解離定数(Pka):
- 12.82±0.46(Predicted)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCA780100 |
AS-703026
AS-703026 |
1236699-92-5 |
250mg |
￥383100 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01MAS120588 |
(S)-N-(2,3-Dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide |
1236699-92-5 |
5g |
￥689100 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01MAS120588 |
(S)-N-(2,3-Dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide |
1236699-92-5 |
10g |
￥1378200 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCA780100 |
AS-703026 |
1236699-92-5 |
25mg |
￥49000 |
2023-06-01 |
購入 |
ピマセルチブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, マイトジェン活性化細胞外シグナル関連キナーゼ(MEK)阻害薬
使用
AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM). AS703026 induces pleiotropic anti-myeloma activity in vitro and in vivo. MEK inhibitors are useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation.
酵素阻害剤
This novel and orally bioavailable MEK1/2 inhibitor (FW = 431.20 g/mol; CAS 1236699-92-5), also known as (S)-N-(2,3-dihydroxypropyl)-3-((2- fluoro-4-iodophenyl)amino)-isonicotinamide, selectively targets MEK1/2 (noncompetitive, with IC50 values of 5-11 nM). AS703026 reduces the growth and survival of multiple myeloma (MM) cells. It also inhibits cytokine-induced osteoclast differentiation about 10x more potently than AZD6244. Inhibition of proliferation by AS703026 leads to G0-G1 cell cycle arrest, attended by reduction in MAF oncogene expression. AS703026 also induces apoptosis (via Caspase-3) as well as poly(ADP- ribose) polymerase (PARP) cleavage in MM cells, whether in the absence or presence of bone marrow stromal cells (BMSCs). Importantly, AS703026 also sensitizes MM cells to other anti-MM therapies employing dexamethasone, melphalan, lenalidomide, perifosine, bortezomib, or rapamycin. Growth reduction in mice bearing H929 MM xenograft tumors correlates with down-regulated pERK1/2, induced PARP cleavage, and decreased microvasculature. BMSC-induced viability of MM patient cells was similarly blocked within the same dose range.
ピマセルチブ 上流と下流の製品情報
原材料
準備製品
ピマセルチブ 生産企業
Global( 146)Suppliers
1236699-92-5(ピマセルチブ)キーワード:
- 1236699-92-5
- AS703026
- N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide
- (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylaMino)isonicotinaMide
- 4-PyridinecarboxaMide, N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)aMino]-
- MSC1936369B
- PiMasertib (AS-703026)
- AS703026/MSC1936369B
- PiMasertib
- SAR 245509
- AS703026 (Pimasertib)
- AS-703026, Pimasertib,MSC1936369B
- PIMASERTIB (AS-703026);MSC1936369B;AS703026
- 100330
- CS-2173
- CS-397
- PIMASERTIB; MSC1936369B; AS-703026; AS 703026; PIMASERTIB; MSC1936369B; AS-703026; AS 703026
- MSC1936369B;PIMASERTIB
- AS703026 ISO 9001：2015 REACH
- Pimasertib (SAR245509, AS703026, MSC1936369B)
- Pimasertib AS703026 AS-703026
- AS703026 N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamide
- N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamide
- ピマセルチブ
- N-[(2S)-2,3-ジヒドロキシプロピル]-3-[(2-フルオロ-4-ヨードフェニル)アミノ]ピリジン-4-カルボキサミド
- N-[(S)-2,3-ジヒドロキシプロピル]-3-[(2-フルオロ-4-ヨードフェニル)アミノ]ピリジン-4-カルボアミド